High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL–ARF Bidirectional Promoter
Authors:
- Kinan Drak AlsibaiKinan Drak Alsibai
- Sophie VacherSVSophie Vacher
- Didier MeseureDMDidier Meseure
- Andre NicolasANAndre Nicolas
- Marick LaeMarick Lae
- Anne SchnitzlerASAnne Schnitzler
- Walid ChemlaliWCWalid Chemlali
- Jerome CrosJerome Cros
- Elisabeth LongchamptELElisabeth Longchampt
- Wulfran CacheuxWCWulfran Cacheux
- Geraldine PignotGPGeraldine Pignot
- Celine CallensCCCeline Callens
Open Access
- 21 August 2019
- journal article
- research article
- Published by MDPI AG in Non-Coding RNA
- Vol. 5 (3) , 44
Abstract
The CDKN2B-AS1 gene, also called ANRIL, is located at the human CDKN2A/B locus at 9p21.3 and transcribed by RNA polymerase II into a long non-coding RNA of 3834 bp. The CDKN2B-AS1 gene overlaps a critical region of 125 kb covering the CDKN2B gene. The CDKN2A/B locus encompasses three major tumor suppressors juxtaposed and joined into a p16-CDKN2A/p15-CDKN2B/p14-ARF gene cluster. CDKN2A encodes splice variants p16-CDKN2A and p14-ARF, and CDKN2B encodes p15-CDKN2B. ANRIL shares a bidirectional promoter with the p14-ARF gene and is transcribed from the opposite strand to the cluster. We performed an analysis of the expression level of ANRIL and tumor suppressor p16-CDKN2A, p15-CDKN2B, and p14-ARF genes using quantitative RT-PCR in a multitumor panel. We observed the overexpression of the four genes ANRIL, p16-CDKN2A, p15-CDKN2B, and p14-ARF in the great majority of the 17 different cancer types. ANRIL was upregulated in 13/17 tumors compared to normal tissues, ranging from 5% (prostate cancer) to 91% (cervix cancer), with variable expression of p16-CDKN2A, p15-CDKN2B, and p14-ARF genes. A high positive correlation was identified between levels of expression of ANRIL and the three tumor suppressors. The strongest positive association was observed with p14-ARF (p < 0.001) in all but one (lung squamous cell carcinoma) of the examined tumor types. This correlation suggests coordinated deregulated mechanisms in all cancer types through aberrant activation of a bidirectional p14-ARF/ANRIL promoter. Furthermore, significant positive correlation was unexpectedly established in prostatic carcinomas, in contradiction with previous data.Keywords
This publication has 38 references indexed in Scilit:
- Resequencing and Clinical Associations of the 9p21.3 RegionCirculation, 2013
- Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor geneOncogene, 2010
- Expression of Linear and Novel Circular Forms of an INK4/ARF-Associated Non-Coding RNA Correlates with Atherosclerosis RiskPLOS Genetics, 2010
- ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1Oncology Reports, 2010
- Molecular Interplay of the Noncoding RNA ANRIL and Methylated Histone H3 Lysine 27 by Polycomb CBX7 in Transcriptional Silencing of INK4aMolecular Cell, 2010
- Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL ExpressionPLOS Genetics, 2010
- CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locusBiochemical and Biophysical Research Communications, 2010
- Ezh1 and Ezh2 Maintain Repressive Chromatin through Different MechanismsMolecular Cell, 2008
- Epigenetic silencing of tumour suppressor gene p15 by its antisense RNANature, 2008
- An evaluation of new criteria for CpG islands in the human genome as gene markersBioinformatics, 2004